Paramount Skydance Corporation (NASDAQ: PSKY) saw its shares climb sharply in premarket trading on Monday, September 21, 2026, following a Reuters report that the company is in advanced settlement discussions with California's attorney general. The stock was up $0.654, or 6.41%, to $10.864 at 09:16 ET, with roughly 156,136 shares changing hands before the opening bell.
The reported negotiations center on a potential $1.5 billion production commitment in California—a move that could help clear a major regulatory hurdle blocking the proposed Warner Bros. Discovery transaction. According to Reuters, the talks also include keeping both studio lots operational and possible penalties if Paramount fails to meet a 30-film annual production pledge. These remain reported negotiating terms, not company guidance.
The urgency stems from a ticking fee: after September 30, Paramount would be liable for $7 million per day until the merger closes. The reported settlement, if finalized, could eliminate that obligation, which over a 214-day period would amount to roughly $1.5 billion—a figure that aligns with the reported production commitment.
California's Attorney General Rob Bonta had earlier expressed concerns about corporate concentration, stating in July, “When too few corporations have too much power … it makes things more expensive, and it makes things worse.” That stance led to a standstill agreement that bars the merger until five days after a merits ruling or June 1, 2027, whichever comes first. A settlement could alter that timeline, but neither party has confirmed an agreement.
Investors are also weighing the financial implications for the equity syndication price. A Paramount filing sets the future equity-syndication price based on a 20-day volume-weighted average price (VWAP), subject to a $12.00 floor and $16.02 ceiling. At the premarket price of $10.864, the floor is 10.5% higher and the ceiling is 47.5% higher, though these are calculations, not projections.
The timing of any settlement is crucial, as the syndication price formula is tied to the pre-closing trading window. A longer delay could pressure the deal's economics, especially given the $7 million daily ticking fee. Analyst views are mixed: Barclays has a Sell rating with an $8 target, Bernstein also rates it Sell with a $12 target, while Citizens is more optimistic with a Market Outperform and $14 target. The broader consensus from a 22-analyst poll averages $9.86, below the current premarket price.
Risks remain elevated. The talks could fail, proposed concessions might be more costly than expected, or the court case could still delay the closing. A higher production bill or a longer timetable would undermine the synergy case and the future equity structure. Investors will be watching for any settlement filing, public statements, or changes to the closing timetable, as well as whether the premarket gains hold at the regular open.
